Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Controlled and Double Blind Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites (CICAFAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03334656
Recruitment Status : Recruiting
First Posted : November 7, 2017
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:

Cell-based engineered skin substitutes are promising to treat difficult-to-heal acute and chronic wounds such as large/deep burns, ulcers resistant to conventional therapies or surgical wounds. Cultured autologous epidermal cell-based therapy is used for more than two decades as permanent wound coverage for large burns. Although this technique has been shown to improve outcomes in patients with large burn injuries, its clinical use is limited by the creation of a second wound at the donor site, the three-week delay needed to obtain sufficient amounts of cells, and the absence of a dermal component resulting in low graft take and wound contraction.

Concurrently, allogeneic cell-based engineered skin substitutes have been proposed. Where they offer off-the-shelf temporary wound coverage acting as biologically active dressings releasing growth factors, cytokines and extra cellular matrix components essential for proper wound healing, they are susceptible of immune rejection that is their major weakness Fetal skin, before the third trimester of gestational age, heals rapidly without scar formation conversely to adult skin. Minimal inflammation, specific cytokine and growth factor profiles, and faster and organized deposit and turnover of Extra Cellular Matrix (ECM) components during fetal wound healing have been proposed to explain the absence of scar formation. Because of their low immunogenicity, and their unique regeneration properties, fetal skin cells represent an attractive alternative to the commonly used autologous and allogenic cutaneous grafts.

The investigators developed a new healing dressing constituted by a collagen sponge seeded with a specific ratio of active fetal fibroblasts and keratinocytes producing a variety of wound healing growth factors and cytokines which increase the speed of wound healing, induce an immunotolerant state, with a low inflammatory reaction.

This prospective randomized controlled study aims to compare wound healing of CICAFAST versus conventional treatment (JELONET®) in the treatment of split-thickness skin graft donor site at D8. The patient will be his own control.


Condition or disease Intervention/treatment Phase
Split Thickness Skin Graft Wound Healing Biological: biological dressing Other: Paraffin gauze dressing Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Controlled and Double Blind Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites
Actual Study Start Date : May 16, 2018
Estimated Primary Completion Date : May 30, 2019
Estimated Study Completion Date : November 16, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Biological Dressing

It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:

  • Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.
  • The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements
Biological: biological dressing
to test a biological dressing on the wound healing of the split-thickness skin graft donor site

Active Comparator: Paraffin Gauze Dressing

It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.

JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.

The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range.

Other: Paraffin gauze dressing
standard intervention : Paraffin gauze dressing on the wound healing




Primary Outcome Measures :
  1. wound healing [ Time Frame: Day 8 ]
    The number of complete healing at D8 judged by blind physician observer. Healing is defined as 80% or more wound closure (determined by a ruler).


Secondary Outcome Measures :
  1. concordance between the healing at D8 (or D11 and D15) judged by blind physician observer and by two experts using photographs [ Time Frame: Day 8 (or D11 and D15 if the healing is not completed) ]
    The healing at D8 (or D11 or D15 if the healing is not completed) judged by blind experts on picture. Healing is defined as 80% or more wound closure (determined by a ruler).

  2. wound healing's rapidity of CICAFAST versus conventional treatment (JELONET®) in the treatment of STSG donor site. [ Time Frame: D8 And D11 (if the healing is not completed) and D15 (if the healing is not completed) ]
    Time to healing (in days) judged by blind physician observer

  3. tolerance of CICAFAST versus the conventional treatment (JELONET®) [ Time Frame: 6 months ]
    AE notification: case of infection (patients with grade 1 or 2 infections controlled by antibiotherapy will stay in the study. Patients with grade 3 or 4 infection will be withdrawn from the trial) and case of biological dressing (CICAFAST) rejection. Immunological monitoring to follow a Cicafast reject of the patient at donor site level.

  4. pain of the wound healing with CICAFAST versus conventional treatment (JELONET®) [ Time Frame: Day 8 And D11 (if the healing is not completed) and D15 (if the healing is not completed) ]
    Number of painful day/wound from the surgery until the complete healing

  5. quality of the wound healing with CICAFAST versus conventional treatment (JELONET®) [ Time Frame: 6 months ]
    Evaluation of the quality of the wound healing by an observer (physician who will not do the patient surgery) at M3 and M6, OSAS (observer scar assessment scale ; 1= normal skin, 10= worst imaginable scar) will be used. By the patient PSAS (patient scar assessment scale ; 1= normal skin, 10= very different) will be used and blind expertise on picture by 2 external experts (Visual Analogue Scale 10 the worst scar to 1 like normal skin). A second evaluation of complete healing will be performed by two exterior independent experts evaluating the photographs taken until complete healing (Healing is defined as 80% or more wound closure)

  6. quality of the wound healing with CICAFAST versus conventional treatment (JELONET®) for the patient who will have confocal microscopy [ Time Frame: 3 months ]
    Results of scars confocal microscopy at M3



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male aged ≥18 years old
  • For potentially childbearing female, only those with effective contraception (contraception pill, implant and intrauterine device) could be included
  • Patient who need skin graft ( height from 100cm2 to 200cm2 and thickness 1.2mm) after surgery excision
  • Patients with social security
  • Patients able to understand and follow the trial instructions
  • Patients who have signed an informed consent

Exclusion Criteria:

  • Patients with an history of cancers of tumors
  • Patients suffering from uncontrolled metabolic disease (for instance diabete), from a psychiatric disorder not treated, with severe arteritis of lower and/or upper limbs, treated with anticoagulant (unless treatment stops 7 days before the surgery), with severe venous insufficiency, suffering of severe polyneuropathy, with known allergy to antibiotics,
  • Patients with an allergic predisposition or known allergy to bovine collagen or silicone
  • Patients receiving corticosteroids, immunosuppressive or cytotoxic agents unless treatment stops 4 weeks before the surgery
  • Patients contraindicated with local anesthetic used in STSG process of his investigator center
  • Patients with systemic infection (all grade defined by CTCAE Common Terminology Criteria for Adverse Event V4.03) at surgery visit will not be included in this trial because of the contraindication of the surgical gesture.
  • Patient intolerant to the conventional treatment (JELONET®)
  • Patient intolerant to the stretchable strip (NYLEX®)
  • Pregnant or breast-feeding women
  • Patients participating in clinical trial
  • Vulnerable people: persons deprived of liberty; under trusteeship or under curatorship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03334656


Contacts
Layout table for location contacts
Contact: Brigitte Dréno, Pr +33240083118 brigitte.dreno@wanadoo.fr

Locations
Layout table for location information
France
Chu de Nantes Recruiting
Nantes, France, 44000
Contact: Pierre Perrot    +33240087302    pierre.perrot@chu-nantes.fr   
CHU de Nantes Not yet recruiting
Nantes, France, 44093
Contact: Brigitte Dréno, Pr    +33240083118    brigitte.dreno@wanadoo.fr   
Sponsors and Collaborators
Nantes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Brigitte Dréno, Pr CHU de Nantes

Layout table for additonal information
Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT03334656     History of Changes
Other Study ID Numbers: RC16_0019
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nantes University Hospital:
Split thickness skin graft donor site
wound healing
Fetal skin bioconstruct
Fibroblasts
Keratinocytes